Blood cancer patients may get transfusions at home in hospice trial
NCT ID NCT06487247
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a new program that gives blood cancer patients access to blood transfusions at home while they receive hospice care. The goal is to see if this improves their quality of life, mood, and reduces hospital visits near the end of life. The trial will include 700 adults with relapsed or refractory blood cancers who are receiving care at Dana-Farber Cancer Institute.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HEME-Hospice program (home blood transfusions combined with hospice care)
What this could lead to
If it works, this could offer blood cancer patients a way to receive comforting transfusions at home while in hospice, potentially improving their quality of life and mood at the end of life.
What could go wrong
This is a behavioral intervention study, not a drug trial, so it won't cure the cancer. The benefit may be modest, and results may not apply to all hospice settings or patient groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••